Amneal Pharmaceuticals has completed the acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialisation. The combination establishes one of the industry’s few fully integrated biosimilars platforms.

Chirag Patel, Co-Founder and Co-Chief Executive Officer, said, “The completion of this acquisition marks a pivotal step in Amneal’s strategy to become America’s #1 Affordable Medicines company. With this acquisition, we have created an integrated biosimilars business that can launch multiple biosimilars each year and extends our growth profile into the next decade.”

The acquisition combines Kashiv’s biologics research, development and manufacturing capabilities with Amneal’s commercial scale, establishing biosimilars as a major long-term growth pillar within the company’s affordable medicines business. The transaction provides Amneal access to the global biosimilars market with more than USD 300 billion projected global biologics loss-of-exclusivity over the next decade. The combined portfolio is expected to support a consistent cadence of biosimilar launches for years to come.

Chintu Patel, Co-Founder and Co-Chief Executive Officer, said, “We are pleased to welcome the Kashiv team to Amneal and thank our shareholders and other stakeholders for their strong support. This acquisition helps to position Amneal to capitalise on an unprecedented wave of biologic loss of exclusivity. Together, we will pursue this significant opportunity and work to expand patient access to high-quality, affordable biologic medicines.”

The transaction builds on a relationship between Amneal and Kashiv spanning more than a decade, providing a strong foundation for integration. Integration planning and related activities are underway and are focused on combining the companies’ development and manufacturing capabilities and advancing the biosimilar pipeline.